GlaxoSmithKline sells out of Aspen
GlaxoSmithKline disposed of its remaining 6.2% stake in Aspen Pharmacare, one of Africa’s largest pharmaceuticals companies, through an accelerated book build launched on Wednesday evening in a deal that was said to be comfortably oversubscribed after a wall-crossing process.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts